Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsSoldano Ferrone, Xinhui Wang
Life of this patent
Estimating the term…
Abstract
It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.
Claims8
A method for diagnosing and treating triple negative-basal breast carcinoma in a subject, comprising
- selecting a subject that has triple negative breast cancer;
- contacting a breast tissue sample obtained from the subject, wherein the subject has triple negative breast cancer, with a detection antibody or antigen binding fragment thereof that specifically binds chondroitin sulfate proteoglycan 4 (CSPG4) for a sufficient amount of time to form an immune complex comprising the detection antibody or antigen binding fragment thereof;
- detecting the presence the immune complex, wherein the presence of an immune complex demonstrates the presence of basal breast carcinoma in the subject;
- and
- administering to the subject an effective amount of a monoclonal antibody or an antigen binding fragment thereof that specifically binds CSPG4, thereby treating the triple negative basal breast cancer in the subject.
Dependencies are inferred from the claim text.